Source:http://linkedlifedata.com/resource/pubmed/id/15588467
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2004-12-13
|
pubmed:abstractText |
This study aimed to evaluate plasminogen activator inhibitor-1 (PAI-1) activity in PCOS. Thirty women with PCOS - 15 normal-weight and 15 obese - and 30 healthy women matched as a group for age and body mass index (BMI) were recruited. The homeostasis model assessment (HOMA) score was significantly elevated in obese compared with normal-weight women, in both PCOS women and controls. HOMA score was significantly higher in both PCOS groups relative to controls. After further adjustment for BMI, PAI-1 activity (IU/ml +/- SD) was significantly higher in the PCOS groups compared with controls. A significant positive correlation was found between HOMA score and BMI in PCOS and control groups. Serum PAI-1 activity was significantly related to BMI and HOMA score. When considering two BMI subgroups, there was no significant difference in the relationship between serum PAI-1 activity and HOMA score in both the control and PCOS groups. No other significant relationship was found between serum PAI-1 activity and any other hormonal or metabolic parameter. In conclusion, women with PCOS have significantly elevated PAI-1 activity independent of obesity, and it is speculated that elevated PAI-1 activity may be a factor in the increased cardiovascular morbidity seen in PCOS.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1472-6483
|
pubmed:author |
pubmed-author:CascellaTeresaT,
pubmed-author:ColaoAnnamariaA,
pubmed-author:Di BiaseSebastianoS,
pubmed-author:LabellaDonatoD,
pubmed-author:LombardiGaetanoG,
pubmed-author:NardoLuciano GLG,
pubmed-author:OrioFrancescoFJr,
pubmed-author:PalombaStefanoS,
pubmed-author:RussoTizianaT,
pubmed-author:SavastanoSilviaS,
pubmed-author:TauchmanovàLibuseL,
pubmed-author:TolinoAchilleA,
pubmed-author:ZulloFulvioF
|
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
505-10
|
pubmed:dateRevised |
2005-4-14
|
pubmed:meshHeading |
pubmed-meshheading:15588467-Adolescent,
pubmed-meshheading:15588467-Adult,
pubmed-meshheading:15588467-Body Mass Index,
pubmed-meshheading:15588467-Body Weight,
pubmed-meshheading:15588467-Cardiovascular Diseases,
pubmed-meshheading:15588467-Female,
pubmed-meshheading:15588467-Humans,
pubmed-meshheading:15588467-Insulin Resistance,
pubmed-meshheading:15588467-Obesity,
pubmed-meshheading:15588467-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:15588467-Polycystic Ovary Syndrome,
pubmed-meshheading:15588467-Risk Factors
|
pubmed:year |
2004
|
pubmed:articleTitle |
Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?
|
pubmed:affiliation |
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy. francescoorio@virgilio.it
|
pubmed:publicationType |
Journal Article
|